Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy

Jin Tian, Long Lin, Jianhua Zang, Peng Liu, Lili Zhao, Hongtao Zhang, Jun XiaoFrontiers in Oncology 2023 · DOI

Abstract

Malignant pleural and peritoneal effusions are frequent complications in advanced lung cancer, typically signaling a poor prognosis. This case report describes a 58-year-old male with advanced ROS1-rearranged lung adenocarcinoma who presented with persistent, treatment-resistant effusions. Following the failure of standard chemotherapy, the patient received a combination of Crizotinib and Anlotinib. This dual-targeted approach led to the rapid resolution of effusions and sustained remission for over four years, suggesting a potent strategy for managing refractory malignant effusions in specific NSCLC subsets.

The Challenge of Malignant Effusions in Advanced NSCLC

Advanced non-small cell lung cancer (NSCLC) often involves the accumulation of excess fluid in the pleural and peritoneal cavities. These malignant effusions are indicators of advanced disease progression, often associated with a median survival of only 3 to 6 months. Patients suffer from significant respiratory distress and abdominal impairment, severely impacting their quality of life.

While Tyrosine Kinase Inhibitors (TKIs) have transformed treatment for patients with genetic drivers like ROS1 rearrangements (found in 1-2% of NSCLC cases), persistent effusions often remain refractory to standard systemic therapies. Conventional management frequently provides only transient relief.

Case Presentation and Therapeutic Strategy

A 58-year-old male patient was diagnosed with advanced lung adenocarcinoma. Initial genetic testing was negative, and the disease progressed through seven cycles of chemotherapy, characterized by worsening pleural and peritoneal effusions. Subsequent high-throughput sequencing identified a ROS1 rearrangement, prompting a novel combination regimen: Crizotinib (250 mg twice daily) to target the ROS1 fusion protein, and Anlotinib (10 mg once daily, 2-weeks-on/1-week-off) to target the VEGF, FGFR, and PDGFR pathways.

Clinical Response and Long-term Outcomes

The patient's response was both rapid and durable. Within one month of treatment initiation, clinical imaging confirmed a dramatic reduction in fluid accumulation.

Baseline CT imaging (August 2018) revealing extensive pleural and peritoneal effusions prior to the combined TKI regimen.

As shown in the baseline imaging, the patient initially presented with significant fluid levels compromising organ function. Following the introduction of the Crizotinib-Anlotinib combination, follow-up scans demonstrated near-complete resolution of these effusions.

Follow-up CT imaging (October 2018) showing significant resolution of effusions after one month of combined Crizotinib and Anlotinib therapy.

The patient achieved stable disease for over four years, far exceeding typical survival expectations. The treatment was well-tolerated, with Grade 2 hypertension being the only notable side effect, managed successfully with standard medication.

Mechanistic Insights: A Dual-Targeted Approach

The success of this "double-hit" strategy likely arises from synergistic molecular mechanisms. Crizotinib directly inhibits the ROS1 signaling pathway driving tumor proliferation, while Anlotinib targets the Vascular Endothelial Growth Factor (VEGF) pathway. VEGF is a primary driver of capillary permeability; by inhibiting it, Anlotinib directly addresses the physiological cause of fluid leakage. Furthermore, anti-angiogenic agents may help overcome potential resistance to Crizotinib by altering the tumor microenvironment.

Conclusion

This case highlights the potential of combining targeted TKIs with anti-angiogenic agents to manage complex, refractory symptoms in advanced NSCLC. While further validation through multicenter clinical trials is necessary, this regimen represents a viable strategy to improve both survival and quality of life for patients with ROS1-rearranged lung adenocarcinoma and persistent malignant effusions.

Summary updated

Abstract

Malignant pleural and peritoneal effusion are common clinical manifestations in advanced malignant tumors, associated with a poor prognosis. This article presents a case of advanced lung adenocarcinoma with ROS1 rearrangement, characterized by persistent malignant pleural and peritoneal effusion. The patient received combined therapy of Crizotinib and Anlotinib, resulting in a significant reduction and even disappearance of the malignant effusion. Exploratory use of this treatment approach improved the patient's quality of life and holds potential for extending overall survival. However, given the single case report nature, the efficacy of this regimen in treating advanced ROS1-rearranged lung adenocarcinoma should be considered as a supplementary strategy, warranting further validation through multicenter clinical data.
BibTeX
@inproceedings{tian2023case,
  author = {Jin Tian and Long Lin and Jianhua Zang and Peng Liu and Lili Zhao and Hongtao Zhang and Jun Xiao},
  title = {{Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1191522},
}
Figure